Pfizer IP head says that IP protectionism in India is discouraging foreign investment

Managing IP is part of Legal Benchmarking Limited, 4 Bouverie Street, London, EC4Y 8AX

Copyright © Legal Benchmarking Limited and its affiliated companies 2025

Accessibility | Terms of Use | Privacy Policy | Modern Slavery Statement

Pfizer IP head says that IP protectionism in India is discouraging foreign investment

Pfizer’s chief IP counsel decries India’s “protectionist intellectual property regime” in testimony before the United States Congress, reports the Financial Times

Speaking at a hearing before the House of Representatives on Wednesday, Roy Waldron of Pfizer argued that India’s intellectual property laws favoured local industries at the expense of international companies. He pointed to the recent revocation of his company’s patent for cancer drug sutent as evidence of an increasingly protectionist IP regime. According to Waldron, the situation has worsened and is discouraging international investment in India.

Waldron also criticised India’s likely increasing use of compulsory licences, even though he claims that Pfizer is “more than willing to discuss viable solutions to increase access to quality medicines”.

Waldron’s comments reflect growing concerns about patent rights in India. Last week, the Intellectual Property Appellate Board (IPAB) upheld the country’s first compulsory licence issued for Bayer's sorafenib. In an interview with Managing IP, IPAB Chairperson Prabha Sridevan defended the board’s decision, calling compulsory licensing a “balanced approach” to protecting the interests of rights holders and the general public.

“Compulsory licences are not a denigration of the owner’s rights,” she argued. “The patent rights are intact until the patent is invalidated.”

The Indian government has indicated that more compulsory licences are almost certainly coming. While the sorafenib compulsory licence was issued under section 84 of the Patent Act, which requires an application from a generic manufacturer, the government itself recently initiated proceedings for three more compulsory licences. The Department of Pharmaceuticals, which initiated the proceedings, relied on section 92, which allows the government to issue compulsory licences in the case of “national emergency or in circumstances of extreme urgency”.

more from across site and SHARED ros bottom lb

More from across our site

Andrea Stone explains how her in-house experience gives her a unique perspective, and why Ballard Spahr’s combination with Lane Powell made it an ideal time to join
The pair had been fighting in multiple jurisdictions but have agreed to settle all litigation
Law firms may try to relate PTAB briefs to broader economic concerns in response to the USPTO’s latest guidance
IP Inclusive’s 10-year celebration provides reasons to be positive in the face of troubling attacks against DEI initiatives
Microsoft allegedly uses the HEVC technology in a range of products and offers an extension as an add-on
A group of five lawyers who joined Cleary Gottlieb say they want to help expand the firm’s IP litigation practice
As we build up to another busy year for the IP STARS rankings and our Managing IP Awards, we assess some of the major IP firms and trends in Germany
Florina Firaru discusses making new connections, the art of flower arranging, and the biggest misconception about IP
The firm, which appointed three IP partners from A&O Shearman, wants to develop a tier one practice in Europe
The England and Wales appeals court handed down its judgment just seven working days after hearing the trademark dispute involving pharma company Merck
Gift this article